Gefitinib Versus Pemetrexed for Previously Treated NSCLC Patients

G

Gachon University Gil Medical Center

Status and phase

Completed
Phase 2

Conditions

Previous Treated Metastatic Non-small Cell Lung Cancer

Treatments

Drug: Gefitinib
Drug: Pemetrexed

Study type

Interventional

Funder types

Other

Identifiers

NCT01783834
2008-GIRBA-1739

Details and patient eligibility

About

To compare the efficacy of gefitinib versus pemetrexed as second-line chemotherapy for patients with previous treated non-small cell lung cancer

Enrollment

95 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Cells pathologically diagnosed as histological or radical surgery or radiation therapy is not possible stage IIIB and stage IV non-small-cell lung cancer patients
  • second line
  • ECOG 0~2
  • Patients with normal liver function and renal function

Exclusion criteria

  • Patients with severe acute infection requiring antibiotic therapy
  • Patients who have received treatment in other areas of cancer within 5 years
  • During pregnancy and lactation patients

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

95 participants in 2 patient groups

pemetrexed
Active Comparator group
Description:
pemetrexed
Treatment:
Drug: Pemetrexed
gefitinib
Active Comparator group
Description:
gefitinib
Treatment:
Drug: Gefitinib

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems